foxo4-dri senolytic peptide study — 10mg | D-Retro-Inverso PPI FOXO4-DRI: Human Trial Status, Cancer

In the SELECT trial, over an average of 40 weeks of follow-up, a 20% reduction in the occurrence of the three-point composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) was found in overweight and obese, non-diabetic adults with once-weekly subcutaneous semaglutide (2.4 mg) [83]

FOXO4-DRI (Proxofim) FOXO4-DRI (Proxofim) is a synthetic peptide studied for its ability to target senescent cells by disrupting FOXO4p53 interactions

Perfect for post-workout, hangovers, or general fatigue

BPC-157 is a different peptide derived from a protein in the human stomach

It is believed to promote healing in muscles, tendons, and ligaments

When B12 is low, you might feel tired, weak, confused, or irritable